Clinical trial
Weekly Taxol Plus Xeloda® vs Taxotere q3wk Plus Xeloda® in the Treatment of…
NCT00201435 · Norwegian Breast Cancer Group, Other · Completed
Key facts
| NCT number | NCT00201435 |
|---|---|
| Title | Weekly Taxol Plus Xeloda® vs Taxotere q3wk Plus Xeloda® in the Treatment of Metastatic BC |
| Official title | Weekly Taxol® Plus Xeloda® Versus Taxotere® Every Three Weeks Plus Xeloda® in the Treatment of Metastatic Breast Cancer A Phase II/III Study |
| Lead sponsor | Norwegian Breast Cancer Group, Other |
| Status | Completed |
| Phase | Phase 2/Phase 3 |
| Study type | Interventional |
| Conditions | Breast Neoplasm |
| Intervention type | Drug |
| Interventions | Paclitaxel weekly in combination with capecitabine, Docetaxel every 3 week in combination with capecitabine |
| Enrollment | 224 |
| Start date | Mar 1, 2005 |
| Primary completion | Jan 1, 2008 |
| Completion | May 1, 2008 |
| First posted | Sep 20, 2005 |
| Last update posted | May 20, 2008 |
| Countries | Norway |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: